{"hands_on_practices": [{"introduction": "A core task in developmental psychopathology is to quantify the population-level impact of early risk factors on later mental illness. The population attributable fraction (PAF) is a key epidemiological metric that achieves this by estimating the proportion of disease cases that could hypothetically be averted if a specific risk factor were eliminated. This exercise [@problem_id:4722781] provides hands-on practice in calculating the PAF, translating a research finding (an adjusted risk ratio) into a powerful statement about public health and prevention priorities.", "problem": "A national longitudinal birth cohort study in psychiatry investigates the life course impact of Adverse Childhood Experiences (ACEs) on adult Major Depressive Disorder (MDD). The exposure is defined as experiencing $\\geq 3$ ACEs before age $18$ years versus $$3 ACEs. In the adult follow-up, the prevalence of exposure to $\\geq 3$ ACEs is $0.25$. A log-binomial regression model adjusting for measured confounders (parental socioeconomic status, parental mental illness, and childhood physical health) estimates the adjusted risk ratio for MDD associated with exposure to $\\geq 3$ ACEs as $2.1$. Under standard causal inference assumptions (consistency, exchangeability, and positivity), and interpreting the adjusted risk ratio as a causal risk ratio for the dichotomized exposure, calculate the population attributable fraction for MDD due to exposure to $\\geq 3$ ACEs in this cohort.\n\nExpress your final answer as a decimal and round to $4$ significant figures. Do not use a percentage sign.", "solution": "We aim to compute the population attributable fraction (PAF) for Major Depressive Disorder (MDD) due to exposure to $\\geq 3$ Adverse Childhood Experiences (ACEs). The PAF is defined as the proportion of cases in the population that would not occur if the exposure were eliminated, under a causal interpretation. Formally, letting $D$ denote the occurrence of MDD and $E$ denote exposure ($E=1$ for $\\geq 3$ ACEs, $E=0$ for $$3 ACEs), the PAF can be defined as\n$$\n\\text{PAF} \\equiv \\frac{P(D) - P^{\\ast}(D)}{P(D)},\n$$\nwhere $P(D)$ is the observed population risk (or prevalence) of $D$ and $P^{\\ast}(D)$ is the counterfactual population risk if, contrary to fact, the exposure were eliminated and all individuals had the risk under $E=0$. Under consistency and exchangeability (no residual confounding) and positivity, $P^{\\ast}(D)$ can be identified as $P(D \\mid E=0)$ in the target population.\n\nLet $p_{e} \\equiv P(E=1)$ denote the prevalence of exposure, $R_{1} \\equiv P(D \\mid E=1)$ the risk among the exposed, and $R_{0} \\equiv P(D \\mid E=0)$ the risk among the unexposed. The observed population risk is the mixture\n$$\nP(D) = p_{e} R_{1} + (1 - p_{e}) R_{0}.\n$$\nEliminating exposure sets the population risk to\n$$\nP^{\\ast}(D) = R_{0}.\n$$\nTherefore,\n$$\n\\text{PAF} = \\frac{p_{e} R_{1} + (1 - p_{e}) R_{0} - R_{0}}{p_{e} R_{1} + (1 - p_{e}) R_{0}} = \\frac{p_{e}(R_{1} - R_{0})}{p_{e} R_{1} + (1 - p_{e}) R_{0}}.\n$$\nExpress the numerator and denominator in terms of the risk ratio $\\text{RR} \\equiv \\frac{R_{1}}{R_{0}}$. Substituting $R_{1} = \\text{RR} \\cdot R_{0}$, we have\n$$\n\\text{PAF} = \\frac{p_{e} R_{0} (\\text{RR} - 1)}{p_{e} R_{0} \\text{RR} + (1 - p_{e}) R_{0}} = \\frac{p_{e} (\\text{RR} - 1)}{1 + p_{e} (\\text{RR} - 1)}.\n$$\n\nWe are given $p_{e} = 0.25$ and an adjusted risk ratio $\\text{RR} = 2.1$. Substituting these into the expression:\n$$\n\\text{PAF} = \\frac{0.25 \\times (2.1 - 1)}{1 + 0.25 \\times (2.1 - 1)} = \\frac{0.25 \\times 1.1}{1 + 0.25 \\times 1.1}.\n$$\nCompute the numerator and denominator:\n$$\n0.25 \\times 1.1 = 0.275, \\quad 1 + 0.275 = 1.275,\n$$\nso\n$$\n\\text{PAF} = \\frac{0.275}{1.275} = \\frac{11}{51} \\approx 0.2156862745\\ldots\n$$\nRounded to $4$ significant figures, the PAF is\n$$\n0.2157.\n$$\n\nThus, under the stated assumptions, approximately $0.2157$ of MDD cases in the population are attributable to exposure to $\\geq 3$ ACEs, expressed as a decimal without a percentage sign.", "answer": "$$\\boxed{0.2157}$$", "id": "4722781"}, {"introduction": "Moving from population-level risks to individual prognoses, a central challenge in developmental psychiatry is predicting future outcomes for high-risk individuals. The clinical utility of any predictive tool, such as a biomarker, is not determined by its sensitivity and specificity alone; it is critically dependent on the base rate of the outcome in the target population. This exercise [@problem_id:4722814] uses Bayes' theorem to calculate positive and negative predictive values, providing a foundational understanding of how to interpret test results in a real-world clinical context and avoid common fallacies.", "problem": "In a cohort of adolescents and young adults identified as clinically high-risk for psychosis, consider the binary diagnostic yield of a baseline biomarker evaluated against the developmental outcome of transition to psychosis over a fixed horizon of $2$ years. Let the event $D$ denote transition to psychosis within $2$ years, and let the biomarker test result be $+$ (positive) or $-$ (negative). The cohort’s base rate (pre-test probability) of $D$ over $2$ years is $P(D)=0.20$. The biomarker has sensitivity $P(+|D)=0.70$ and specificity $P(-|\\neg D)=0.80$. Using the fundamental definitions of sensitivity and specificity, the law of total probability, and Bayes’ theorem, derive the expressions for the positive predictive value (PPV) $P(D|+)$ and the negative predictive value (NPV) $P(\\neg D|-)$, and compute their numerical values for this cohort. Express each value as a decimal and round each to four significant figures.", "solution": "The problem provides the following information:\nThe event of transitioning to psychosis within a $2$-year horizon is denoted by $D$.\nThe prior probability, or base rate, of this event is $P(D) = 0.20$.\nA biomarker test can yield a positive ($+$) or negative ($-$) result.\nThe sensitivity of the test is the probability of a positive result given the presence of the condition, $P(+|D) = 0.70$.\nThe specificity of the test is the probability of a negative result given the absence of the condition, $P(-|\\neg D) = 0.80$, where $\\neg D$ denotes the event of not transitioning to psychosis.\n\nWe are tasked with deriving the expressions for the positive predictive value (PPV), $P(D|+)$, and the negative predictive value (NPV), $P(\\neg D|-)$, and then computing their numerical values.\n\nFirst, we determine the probabilities of the complementary events, which are necessary for the subsequent derivations.\nThe probability of not transitioning to psychosis is:\n$$P(\\neg D) = 1 - P(D) = 1 - 0.20 = 0.80$$\nThe probability of a positive test result given the absence of the condition (the false positive rate) is the complement of the specificity:\n$$P(+|\\neg D) = 1 - P(-|\\neg D) = 1 - 0.80 = 0.20$$\nThe probability of a negative test result given the presence of the condition (the false negative rate) is the complement of the sensitivity:\n$$P(-|D) = 1 - P(+|D) = 1 - 0.70 = 0.30$$\n\nNow, we derive the expression for the positive predictive value (PPV), $P(D|+)$. By the definition of conditional probability (which is a rearrangement of the definition of joint probability, $P(A \\cap B) = P(A|B)P(B)$), we have:\n$$P(D|+) = \\frac{P(D \\cap +)}{P(+)}$$\nThe numerator, $P(D \\cap +)$, can be expressed using the definition of conditional probability as $P(+|D)P(D)$.\nThe denominator, $P(+)$, is the marginal probability of a positive test result. We can expand this term using the law of total probability, conditioning on the event $D$ and its complement $\\neg D$:\n$$P(+) = P(+|D)P(D) + P(+|\\neg D)P(\\neg D)$$\nSubstituting these expressions back into the formula for $P(D|+)$ gives us Bayes' theorem for this context:\n$$P(D|+) = \\frac{P(+|D)P(D)}{P(+|D)P(D) + P(+|\\neg D)P(\\neg D)}$$\nThis is the general expression for the positive predictive value. We now substitute the given numerical values:\n$$P(D|+) = \\frac{(0.70)(0.20)}{(0.70)(0.20) + (0.20)(0.80)} = \\frac{0.14}{0.14 + 0.16} = \\frac{0.14}{0.30}$$\n$$P(D|+) \\approx 0.46666...$$\nRounding to four significant figures, the positive predictive value is $0.4667$.\n\nNext, we derive the expression for the negative predictive value (NPV), $P(\\neg D|-)$. Following a similar procedure, the definition of conditional probability gives:\n$$P(\\neg D|-) = \\frac{P(\\neg D \\cap -)}{P(-)}$$\nThe numerator can be expressed as $P(-|\\neg D)P(\\neg D)$.\nThe denominator, $P(-)$, is the marginal probability of a negative test result. Using the law of total probability:\n$$P(-) = P(-|D)P(D) + P(-|\\neg D)P(\\neg D)$$\nAlternatively, since there are only two outcomes for the test, $P(-) = 1 - P(+)$. We have already calculated $P(+) = 0.30$, so $P(-) = 1 - 0.30 = 0.70$.\nSubstituting the expanded expressions into the formula for $P(\\neg D|-)$ yields the Bayesian formulation for NPV:\n$$P(\\neg D|-) = \\frac{P(-|\\neg D)P(\\neg D)}{P(-|D)P(D) + P(-|\\neg D)P(\\neg D)}$$\nThis is the general expression for the negative predictive value. We substitute the numerical values:\n$$P(\\neg D|-) = \\frac{(0.80)(0.80)}{(0.30)(0.20) + (0.80)(0.80)} = \\frac{0.64}{0.06 + 0.64} = \\frac{0.64}{0.70}$$\n$$P(\\neg D|-) \\approx 0.9142857...$$\nRounding to four significant figures, the negative predictive value is $0.9143$.\n\nThus, the derived values for the positive predictive value and negative predictive value are approximately $0.4667$ and $0.9143$, respectively.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.4667  0.9143\n\\end{pmatrix}\n}\n$$", "id": "4722814"}, {"introduction": "After identifying risk and making a diagnosis, the next step is intervention, which must be tailored to the individual's developmental context. This problem [@problem_id:4722843] grounds psychopharmacological practice in first principles, beginning with a fundamental dose calculation and expanding into the nuanced clinical reasoning required for safe and effective medication titration. By connecting a drug's pharmacodynamic profile to a patient's comorbidities and developmental stage, this practice develops the critical thinking skills necessary for personalized and evidence-based treatment planning across the lifespan.", "problem": "A child diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) is being considered for a stimulant medication with a target weight-normalized daily dose of $0.8$ $\\mathrm{mg/kg/day}$. The child weighs $30$ $\\mathrm{kg}$. Using only core pharmacological definitions of dose normalization and dimensional consistency, derive the absolute daily dose in $\\mathrm{mg/day}$ from first principles and compute its value. Round your final numeric result to two significant figures and express it in $\\mathrm{mg/day}$.\n\nThen, based on established developmental psychopathology and psychopharmacology principles, discuss when dose titration should proceed more slowly due to comorbidities across the lifespan (for example, cardiac, neurologic, tic, anxiety, mood, developmental, and substance-related disorders), justifying the rationale at the level of mechanism or risk. Your discussion should be grounded in fundamental facts about stimulant pharmacodynamics (for example, sympathomimetic effects and catecholamine reuptake inhibition) and developmental considerations (for example, maturation of organ systems and neurodevelopmental vulnerabilities), without relying on prespecified titration algorithms.\n\nProvide the final numeric dose in $\\mathrm{mg/day}$ as a single number, rounded to two significant figures.", "solution": "The problem requires a two-part response: first, a calculation of the absolute daily dose of a stimulant medication for a child with ADHD, and second, a discussion of the principles guiding slower dose titration in the presence of specific comorbidities.\n\n**Part 1: Calculation of Absolute Daily Dose**\n\nThe calculation is to be derived from first principles, relying on dimensional consistency.\n\nLet $D_{norm}$ represent the weight-normalized daily dose, $m$ represent the child's body mass, and $D_{abs}$ represent the absolute daily dose.\n\nThe givens from the problem statement are:\n-   Weight-normalized daily dose, $D_{norm} = 0.8 \\, \\mathrm{mg/kg/day}$.\n-   Child's mass, $m = 30 \\, \\mathrm{kg}$.\n\nThe unit of $D_{norm}$ is mass of drug per unit body mass per unit time. The unit of $m$ is body mass. The desired unit for $D_{abs}$ is mass of drug per unit time ($\\mathrm{mg/day}$).\n\nTo obtain the units of $D_{abs}$ from the units of $D_{norm}$ and $m$, we must perform a multiplication. The relationship is defined as:\n$$D_{abs} = D_{norm} \\times m$$\n\nWe can verify this through dimensional analysis:\n$$[\\text{Units of } D_{abs}] = [\\text{Units of } D_{norm}] \\times [\\text{Units of } m]$$\n$$\\frac{\\mathrm{mg}}{\\mathrm{day}} = \\frac{\\mathrm{mg}}{\\mathrm{kg} \\cdot \\mathrm{day}} \\times \\mathrm{kg}$$\nThe $\\mathrm{kg}$ units cancel, yielding the correct units for the absolute daily dose.\n\nNow, we substitute the given numerical values into the equation:\n$$D_{abs} = 0.8 \\, \\frac{\\mathrm{mg}}{\\mathrm{kg} \\cdot \\mathrm{day}} \\times 30 \\, \\mathrm{kg}$$\n$$D_{abs} = 24 \\, \\frac{\\mathrm{mg}}{\\mathrm{day}}$$\n\nThe problem requires the final numeric result to be rounded to two significant figures. The calculated value of $24$ already contains two significant figures ($2$ and $4$). Therefore, no further rounding is necessary.\n\nThe absolute daily dose is $24 \\, \\mathrm{mg/day}$.\n\n**Part 2: Discussion of Slower Dose Titration**\n\nThe principle of dose titration involves gradually increasing a medication's dose to find the optimal point that maximizes therapeutic benefit while minimizing adverse effects. Slower titration is a risk-mitigation strategy employed when a patient has comorbidities that either increase their vulnerability to the medication's known side effects or when the medication could potentially worsen the comorbid condition. For stimulant medications, this is grounded in their pharmacodynamic-pharmacokinetic properties and developmental considerations.\n\nStimulants, such as methylphenidate and amphetamine, primarily exert their therapeutic effects by increasing the synaptic concentrations of the catecholamines dopamine ($DA$) and norepinephrine ($NE$). They achieve this by blocking or reversing the action of the dopamine transporter ($DAT$) and the norepinephrine transporter ($NET$). This mechanism, while effective for ADHD, has systemic consequences that necessitate caution in certain populations.\n\n1.  **Cardiac Disorders:** Stimulants are sympathomimetic agents. By increasing synaptic $NE$, they enhance signaling at adrenergic receptors in the peripheral nervous system, including the heart and blood vessels. This pharmacodynamic effect manifests as increases in heart rate and blood pressure. In a child with a pre-existing structural cardiac defect, arrhythmia, or cardiomyopathy, even a modest increase in cardiac workload or electrical irritability can be dangerous. Slow titration is imperative to allow for careful monitoring of vital signs ($HR$, $BP$) at each dose level, ensuring that any adverse cardiovascular response is detected at the lowest possible dose before it becomes clinically significant.\n\n2.  **Tic Disorders and Tourette Syndrome:** The pathophysiology of tic disorders is closely linked to dysregulation in dopamine pathways within the cortico-striatal-thalamo-cortical (CSTC) circuits. While increased $DA$ in the prefrontal cortex is therapeutic for ADHD, the same increase in the basal ganglia can exacerbate motor and vocal tics. This represents a direct conflict in the desired regional effects of the medication. Slower titration allows the clinician to methodically assess the impact on tics at each dose increment. If tics worsen, the dose can be reduced or held, allowing for a careful balancing of ADHD symptom control against tic exacerbation.\n\n3.  **Anxiety Disorders:** Both the body's stress/arousal response and anxiety disorders involve the noradrenergic system, originating from the locus coeruleus. Stimulants, by increasing $NE$ neurotransmission, can produce physiological symptoms such as palpitations, tremor, and a sense of internal restlessness or jitteriness that are phenomenologically indistinguishable from the somatic symptoms of anxiety. In a patient with a pre-existing anxiety disorder, a rapid dose increase can be highly anxiogenic, potentially triggering a panic attack and leading to treatment refusal. A slow titration allows the nervous system to habituate to the increased catecholaminergic tone and helps to distinguish between a therapeutic alerting effect and an adverse anxiogenic one.\n\n4.  **Mood Disorders (especially Bipolar Disorder):** The activating and mood-elevating properties of stimulants, mediated by increased $DA$ and $NE$, pose a significant risk in patients with a personal or strong family history of bipolar disorder. A rapid increase in stimulant dose can induce a switch from a euthymic or depressed state into hypomania or full-blown mania. Thus, in any patient where bipolar disorder is suspected, titration must proceed with extreme caution, often with a concurrent mood stabilizer already on board. Slower titration allows for close monitoring of mood, sleep, energy, and behavior to detect any early signs of mood destabilization.\n\n5.  **Substance Use Disorders (SUDs):** Stimulants have a known potential for misuse and diversion due to their reinforcing effects on the mesolimbic dopamine (reward) pathway. In an adolescent or adult with a history of SUD, there is an elevated risk of misuse. While effectively treating ADHD may ultimately lower the risk of SUD, the initiation of treatment must be managed carefully. Slow titration is one component of a comprehensive risk-management strategy that also includes using long-acting, abuse-deterrent formulations and frequent monitoring for signs of drug-seeking behavior, misuse, or diversion.\n\n6.  **General Developmental Considerations:** A child's body is not a small adult's. Organ systems responsible for drug metabolism (e.g., the liver and its cytochrome $P450$ enzyme system) and elimination (e.g., the kidneys) are still maturing, which can lead to variability in drug clearance and half-life. Furthermore, the brain itself is undergoing profound neurodevelopmental changes, with shifting densities and sensitivities of neurotransmitter receptors and transporters. Because of this dynamic physiological and neurobiological background, a slower, more cautious titration in younger children is a fundamentally prudent approach. It accounts for potential age-dependent differences in pharmacokinetics and pharmacodynamics, reducing the likelihood of unexpected or exaggerated adverse effects.\n\nIn summary, slower titration is not a default but a deliberate, principle-based adjustment for patients with specific vulnerabilities. The rationale is consistently tied to the core mechanism of stimulants and its predictable interaction with the pathophysiology of the comorbid conditions or the developmental state of the patient.", "answer": "$$\\boxed{24}$$", "id": "4722843"}]}